SOURCES ET ETUDES POUR FLOVASANTE

Sources :

1 - Entretien avec Carole Minker, auteur de l'ouvrage 200 plantes qui vous veulent du bien, éditions Larousse2013.
2 - Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials . Liu J, Zhang J, et al. Chin Med. 2006 Nov 23;1:4. ( étude accessible en ligne )
3 - HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. Bogsrud MP, Ose L, et al. Scand Cardiovasc J. 2010 Aug;44(4):197-200. ( étude accessible en ligne )
4 - Hegsted M et al, Stabilized rice bran and oat bran lower cholesterol in humans, Nutrition Research Volume 13, Issue 4, April 1993, Pages 387-398. (étude accessible en ligne )
5 - Nutrivigilance : l'Anses met en consultation un avis sur les compléments alimentaires à base de levure de riz rouge , publié le 17/10/2013.
6 - J Am Diet Assoc. 2003 May;103(5):577-81. Fat-free foods supplemented with soy stanol-lecithin powder reduce cholesterol absorption and LDL cholesterol. Spilburg CA1, Goldberg AC, McGill JB, Stenson WF, Racette SB, Bateman J, McPherson TB, Ostlund RE Jr ( étude accessible en ligne ).
7 - Knuiman JT et al, Lecithin intake and serum cholesterol, Am J Clin Nutr February 1989 vol. 49 n°2 266-268. ( étude accessible en ligne )
8 - Bundy R., et al. Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: A randomized, double blind placebo controlled trial. Phytomedicine, Volume 15, Issue 9, Pages 668-675, 3 September 2008. ( étude accessible en ligne )

La recherche sur la canneberge

Les chercheurs se sont penchés sur les propriétés de la canneberge, et plus particulièrement sur son action bénéfique sur les voies urinaires. L'hypothèse de départ était que la consommation de canneberge acidifiait l'urine, ce qui en rendait le milieu impropre à une colonisation par des germes et des bactéries. Cette hypothèse a, par la suite, été remise en question. Il semble aujourd'hui que les propriétés de la canneberge proviennent de ses substances, qui interagissent avec la composition chimique de l'urine. Grâce à la canneberge, les bactéries ne pourraient pas adhérer aux parois des voies urinaires et seraient donc rapidement éliminées avec la miction.
La première étude systématique et de grande ampleur a été menée en 2008, sur des femmes à risque (10 essais cliniques sur près de 2 000 sujets). Cette étude prouve l'efficacité du jus de canneberge dans la prévention des infections urinaires. Plusieurs études de moindre ampleur ont suivi, chez des jeunes filles, ainsi que chez des femmes enceintes. Si la canneberge se révèle plus efficace qu'un placebo, son efficacité demeure encore à prouver scientifiquement, dans le cas de cystites déclarées.

La recherche sur la busserole

Les chercheurs se sont surtout intéressés à la busserole pour ses propriétés antiseptiques. Le macérat de busserole permettrait également d'atténuer les taches et les imperfections cutanées en clarifiant la peau. Lorsqu'elle est mélangée avec de l'huile de chanvre, elle pénètre dans la peau et agit sur les quantités excessives de mélanine.

Recherche

Des études ont été réalisées et publié par des scientifiques chinois sur les bénéfices d'un apport en collagène marin ingéré, que ce soit pour la peau ou sur les os et tous ont reconnu l'augmentation des cellules de notre épiderme ainsi qu'une densité de la masse osseuse dans le renouvellement pour notre organisme.

Dr C Searling, Fresco CA de la « Harvard Medical School » en Amérique, as effectué des études sur les effets du collagène marin administré par voie orale pour réduire l'inflammation et soulager la douleur et a prouvé de façon concluante que près de 90% des participants ont donné des résultats concluants.

Notes

1. Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists.Hematol Oncol Clin North Am 2000 Apr; 14(2):339-53.
2. USDA National Nutrient Database for Standard Reference, Release 19. [Consulté le 8 juillet 2010] www.nal.usda.gov
3. Ushiroyama T, Ikeda A, Ueki M. Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas. 2002 Mar 25; 41(3):211-21.
4. Takemura H. [Prevention of osteoporosis by foods and dietary supplements. "Kinnotsubu honegenki": a fermented soybean (natto) with reinforced vitamin K2 (menaquinone-7)] Clin Calcium. 2006 Oct; 16(10):119-26. Japanese.
5. Kanai T, Takagi T, et al. Serum vitamin K level and bone mineral density in post-menopausal women.Int J Gynaecol Obstet 1997 Jan; 56(1):25-30.
6. Booth SL, Broe KE, et al. Vitamin K intake and bone mineral density in women and men. Am J Clin Nutr. 2003 Feb; 77(2):512-6. Texte intégral : www.ajcn.org
7. Booth SL, Broe KE, et al. Associations between vitamin K biochemical measures and bone mineral density in men and women. J Clin Endocrinol Metab. 2004 Oct; 89(10):4904-9. Texte intégral : http://jcem.endojournals.org
8. Booth SL, Tucker KL, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr. 2000 May; 71(5):1201-8. Texte intégral : www.ajcn.org
9. Feskanich D, Weber P, et al. Vitamin K intake and hip fractures in women: a prospective study.Am J Clin Nutr 1999 Jan; 69(1):74-9.
10. Vermeer C, Shearer MJ, et al. Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr. 2004 Dec; 43(6):325-35. Review.
11. Bolton-Smith C, Mole PA, et al. Two-year intervention study with phylloquinone (vitamin K1), vitamin D and calcium: effect on bone mineral content. Ann Nutr Metab 2001 45(Suppl. 1):246. Étude citée et résumée dans : Vermeer C, Shearer MJ, et al. Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr. 2004 Dec; 43(6):325-35. Review.
12. Braam LA, Knapen MH, et al. Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int. 2003 Jul; 73(1):21-6.
13. Effect of vitamin K supplementation on bone loss in elderly men and women. Booth SL, Dallal G, et al.J Clin Endocrinol Metab. 2008 Apr; 93(4):1217-23. Epub 2008 Feb 5.
14. Vitamin K, circulating cytokines, and bone mineral density in older men and women. Shea MK, Dallal GE, et al. Am J Clin Nutr. 2008 Aug; 88(2):356-63.
15. Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. Cheung AM, Tile L, et al. PLoS Med. 2008 Oct 14; 5(10):e196. Erratum in: PLoS Med. 2008 Dec; 5(12):e247.
16. Vitamin K to prevent fractures in older women: systematic review and economic evaluation. Stevenson M, Lloyd-Jones M, Papaioannou D. Health Technol Assess. 2009 Sep; 13(45):iii-xi, 1-134. Review.
17. Purwosunu Y, Rachman IA, et al. Vitamin K treatment for postmenopausal osteoporosis in Indonesia.J Obstet Gynaecol Res. 2006; 32:230-4.
18. Iwamoto J, Takeda T, Ichimura S. Treatment with vitamin D3 and/or vitamin K2 for postmenopausal osteoporosis. Keio J Med. 2003 Sep; 52(3):147-50. Review. Texte intégral : www.kjm.keio.ac.jp
19. Whelan AM, Jurgens TM, Bowles SK. Natural health products in the prevention and treatment of osteoporosis: systematic review of randomized controlled trials. Ann Pharmacother. 2006 May; 40(5):836-49. Review.
20. Cockayne S, Adamson J, et al. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2006 Jun 26; 166(12):1256-61. Review.
21. Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. Hirao M, Hashimoto J, et al. J Bone Miner Metab. 2008; 26(3):260-4. Epub 2008 May 11.
22. Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. Inoue T, Fujita T, et al. J Bone Miner Metab. 2009; 27(1):66-75. Epub 2008 Dec 12.
23. Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials. Iwamoto J, Matsumoto H, Takeda T. Clin Drug Investig. 2009; 29(7):471-9. Review.
24. Rejnmark L, Vestergaard P, et al. No effect of vitamin K1 intake on bone mineral density and fracture risk in perimenopausal women. Osteoporos Int. 2006; 17(8):1122-32.
25. Plaza SM, Lamson DW. Vitamin K2 in bone metabolism and osteoporosis. Altern Med Rev. 2005 Mar; 10(1):24-35. Review. Texte intégral : www.thorne.com/altmedrev
26. Adams J, Pepping J. Vitamin K in the treatment and prevention of osteoporosis and arterial calcification. Am J Health Syst Pharm. 2005 Aug 1; 62(15):1574-81. Review.
27. Ryan-Harshman M, Aldoori W. Bone health. New role for vitamin K?Can Fam Physician. 2004 Jul; 50:993-7. Review.
28. Yonemura K, Kimura M, et al. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis.Calcif Tissue Int 2000 Feb;66(2):123-8.
29. Inoue T, Sugiyama T, et al. Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol. Endocr J 2001;48:11-18.
30. Yonemura K, Fukasawa H, et al. Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine. Am J Kidney Dis 2004;43:53-60.
31. Sasaki N, Kusano E, Takahashi H. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab. 2005; 23(1):41-7.
32. Geleijnse JM, Vermeer C, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004 Nov; 134(11):3100-5.
33. Jie KS, Bots ML, et al. Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study. Calcif Tissue Int. 1996; 59:352-6.
34. Jie KS, Bots ML, et al. Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population-based study. Atherosclerosis. 1995 Jul; 116(1):117-23.
35. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Shea MK, O’Donnell CJ, et al. Am J Clin Nutr. 2009 Jun; 89(6):1799-807. Epub 2009 Apr 22.
36. Braam LA, Hoeks AP, et al. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost. 2004 Feb; 91(2):373-80.
37. Barengolts EI, Berman M, et al. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int. 1998; 62:209-13.
38. Hak AE, Pols HA, et al. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol. 2000; 20:1926-31. Texte intégral : http://atvb.ahajournals.org
39. Booth SL, Centurelli MA. Vitamin K: a practical guide to the dietary management of patients on warfarin. Nutr Rev. 1999 Sep; 57(9 Pt 1):288-96. Review.
40. Couris R, Tataronis G, et al. Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices. Int J Vitam Nutr Res. 2006 Mar; 76(2):65-74.
41. Sconce E, Khan T, et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost. 2005 May; 93(5):872-5.
42. Khan T, Wynne H, et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol. 2004 Feb; 124(3):348-54

1. Lin CC, Lu JM, et al. Anti-inflammatory and radical scavenge effects of Arctium lappa.Am J Chin Med. 1996;24(2):127-37.
2. Kardosova A, Machova E. Antioxidant activity of medicinal plant polysaccharides. Fitoterapia. 2006 Jul;77(5):367-73. Epub 2006 May 24.
3. Leonard SS, Keil D, et al. Essiac tea: scavenging of reactive oxygen species and effects on DNA damage.J Ethnopharmacol. 2006 Jan 16;103(2):288-96. Epub 2005 Oct 13.
4. Cho MK, Jang YP, et al. Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: the role in TNF-alpha inhibition. Int Immunopharmacol. 2004 Oct;4(10-11):1419-29.
5. Lin SC, Chung TC, et al. Hepatoprotective effects of Arctium lappa on carbon tetrachloride- and acetaminophen-induced liver damage.Am J Chin Med. 2000;28(2):163-73.
6. Lin SC, Lin CH, et al. Hepatoprotective effects of Arctium lappa Linne on liver injuries induced by chronic ethanol consumption and potentiated by carbon tetrachloride. J Biomed Sci. 2002 Sep-Oct;9(5):401-9.
7. Iwakami S, Wu JB, et al. Platelet activating factor (PAF) antagonists contained in medicinal plants: lignans and sesquiterpenes.Chem Pharm Bull (Tokyo). 1992 May;40(5):1196-8.
8. Gentil M, Pereira JV, et al. In vitro evaluation of the antibacterial activity of Arctium lappa as a phytotherapeutic agent used in intracanal dressings. Phytother Res. 2006 Mar;20(3):184-6.
9. Holetz FB, Pessini GL, et al. Screening of some plants used in the Brazilian folk medicine for the treatment of infectious diseases. Mem Inst Oswaldo Cruz. 2002 Oct;97(7):1027-31.
10. Morita K, Kada T, Namiki M. A desmutagenic factor isolated from burdock (Arctium lappa Linne).Mutat Res. 1984 Oct;129(1):25-31.
11. Ito Y, Maeda S, Sugiyama T. Suppression of 7,12-dimethylbenz[a]anthracene-induced chromosome aberrations in rat bone marrow cells by vegetable juices.Mutat Res. 1986 Oct;172(1):55-60.
12. Awale S, Lu J, et al. Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res. 2006 Feb 1;66(3):1751-7.
13. Matsumoto T, Hosono-Nishiyama K, Yamada H. Antiproliferative and apoptotic effects of butyrolactone lignans from Arctium lappa on leukemic cells. Planta Med. 2006 Feb;72(3):276-8.
14. Tai J, Cheung S. In Vitro culture studies of FlorEssence on human tumor cell lines. Phytother Res. 2005 Feb;19(2):107-12.
15. Natural Standard (Ed). Herbs & Supplements - Burdock (Arctium lappa), Nature Medicine Quality Standard. [Consulté le 28 septembre 2010]. www.naturalstandard.com
16. Sasaki Y, Kimura Y, et al. Anaphylaxis due to burdock.Int J Dermatol. 2003 Jun;42(6):472-3.
17. Natural Arctium lappa fruit extract improves the clinical signs of aging skin. Knott A, Reuschlein K,et al. J Cosmet Dermatol. 2008 Dec;7(4):281-9.

1. Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002 Nov 19;106(21):2747-57. Texte intégral : circ.ahajournals.org
2. International Society for the Study of Fatty Acids and Lipids (ISSFAL). Recommendations for Intake of Polyunsaturated Fatty Acids in Healthy Adults, Grande-Bretagne, 2004. [Consulté le 22 janvier 2010]. www.issfal.org.uk
3. Omega3 Fatty acids for cardioprotection. Lee JH, O'Keefe JH, et al. Mayo Clin Proc. 2008 Mar;83(3):324-32. Texte intégral : www.mayoclinicproceedings.com
4. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. Lavie CJ, Milani RV, et al. J Am Coll Cardiol. 2009 Aug 11;54(7):585-94. Review.
5. Towards Establishing Dietary Reference Intakes for Eicosapentaenoic and Docosahexaenoic Acids. Harris WS, et al, J Nutr, Avril 2009, Vol. 139, No 4, 804S-819S.
6. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. Danaei G, Ding EL, et al. PLoS Med. 2009 Apr 28;6(4):e1000058. Texte intégral : www.plosmedicine.org
7. Fish oil for primary and secondary prevention of coronary heart disease. Roth EM, Harris WS. Curr Atheroscler Rep. 2010 Jan;12(1):66-72. Review.
8. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Marik PE, Varon J. Clin Cardiol. 2009 Jul;32(7):365-72. Review.
9. Zhang J, Sasaki S, et al. Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study.Prev Med. 1999 May;28(5):520-9.
10. He K, Song Y, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation. 2004 Jun 8;109(22):2705-
11. Hooper L, Thompson RL, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ. 2006 Apr 1;332(7544):752-60. Review. Texte intégral : http://bmj.bmjjournals.com
12. Effect of fish oil on arrhythmias and mortality: systematic review. León H, Shibata MC, et al. BMJ. 2008 Dec 23;337:a2931. doi: 10.1136/bmj.a2931. Review. Texte intégral : www.bmj.com
13. Bucher HC, Hengstler P, et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002 Mar;112(4):298-304.
14. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.Lancet. 1999 Aug 7;354(9177):447-55.
15. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Zhao YT, Chen Q, et al. Ann Med. 2009;41(4):301-10.
16. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Rauch B, Schiele R, et al; OMEGA Study Group. Circulation. 2010 Nov 23;122(21):2152-9.
17. n-3 fatty acids and cardiovascular events after myocardial infarction. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. N Engl J Med. 2010 Nov 18;363(21):2015-26.
18. Engler MM, Engler MB. Omega-3 fatty acids: role in cardiovascular health and disease. J Cardiovasc Nurs. 2006 Jan-Feb;21(1):17-24, quiz 25-6. Review.
19. The role of fish oil in hypertension. Yang H, Kenny A. Conn Med. 2007 Oct;71(9):533-8. Review.
20. Effects of fish oil supplementation on markers of the metabolic syndrome. Pedersen MH, Mølgaard C,et al. J Pediatr. 2010 Sep;157(3):395-400, 400.e1.
21. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Eslick GD, Howe PR, et al. Int J Cardiol. 2009 Jul 24;136(1):4-16. Review.
22. Fish oil and the management of hypertriglyceridemia. Mattar M, Obeid O. Nutr Health. 2009;20(1):41-9. Review.
23. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Yokoyama M, Origasa H, et al; Japan EPA lipid intervention study (JELIS) Investigators. Lancet. 2007 Mar 31;369(9567):1090-8.
24.Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Matsuzaki M, Yokoyama M, et al; JELIS Investigators. Circ J. 2009 Jul;73(7):1283-90. Texte intégral www.jstage.jst.go.jp
25. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Tanaka K, Ishikawa Y, et al; JELIS Investigators, Japan. Stroke. 2008 Jul;39(7):2052-8. Texte intégral : stroke.ahajournals.org
26. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Goldberg RJ, Katz J. Pain. 2007 May;129(1-2):210-23.
27. Session 3: Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on 'Nutrition and autoimmune disease' PUFA, inflammatory processes and rheumatoid arthritis. Calder PC. Proc Nutr Soc. 2008 Nov;67(4):409-18. Review.
28. Fish oil and rheumatoid arthritis: past, present and future. James M, Proudman S, Cleland L. Proc Nutr Soc. 2010 Aug;69(3):316-23. Review.
29. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Appleton KM, Rogers PJ, Ness AR. Am J Clin Nutr. 2010 Mar;91(3):757-70. Texte intégral : www.ajcn.org
30. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. Lespérance F, Frasure-Smith N, et al. J Clin Psychiatry. 2010 Jun 15.
31. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. Freeman MP, Fava M, et al. J Clin Psychiatry. 2010 Jun;71(6):669-81. Review.
32. Omega-3 fatty acids in major depressive disorder. Freeman MP. J Clin Psychiatry. 2009;70 Suppl 5:7-11. Review.
33. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. Ravindran AV, Lam RW, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT). J Affect Disord. 2009 Oct;117 Suppl 1:S54-64.
34. The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study. Tajalizadekhoob Y, Sharifi F, et al. Eur Arch Psychiatry Clin Neurosci. 2011 Feb 12.
35. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. Rondanelli M, Giacosa A, et al. J Am Coll Nutr. 2010 Feb;29(1):55-64.
36. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Ross BM, Seguin J, Sieswerda LE. Lipids Health Dis. 2007 Sep 18;6:21. Review. Texte integral : http://www.lipidworld.com
37. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. Martins JG. J Am Coll Nutr. 2009 Oct;28(5):525-42. Review.
38. The efficacy of n-3 fatty acids DHA and EPA (fish oil) for perinatal depression. Jans LA, Giltay EJ, Van der Does AJ. Br J Nutr. 2010 Dec;104(11):1577-85. Review.
39. Role of omega-3 Fatty acids for prevention or treatment of perinatal depression. Borja-Hart NL, Marino J. Pharmacotherapy. 2010 Feb;30(2):210-6. Review.
40. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. Makrides M, Gibson RA, et al; DOMInO Investigative Team. JAMA. 2010 Oct 20;304(15):1675-83.
41. National Institutes of Health. Fish oil studies clinicaltrial.gov
42. Omega-3 fatty acids: potential role in the management of early Alzheimer's disease. Jicha GA, Markesbery WR. Clin Interv Aging. 2010 Apr 7;5:45-61. Review.
43. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. Quinn JF, Raman R, et al. JAMA. 2010 Nov 3;304(17):1903-11.
44. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Yurko-Mauro K, McCarthy D, et al; MIDAS Investigators. Alzheimers Dement. 2010 Nov;6(6):456-64.
45. Woods RK, Thien FC, Abramson MJ. Dietary marine fatty acids (fish oil) for asthma in adults and children. Cochrane Database Syst Rev. 2002;(3):CD001283. Review.
46. Schachter H, Reisman J, et al. Health Effects of Omega-3 Fatty Acids on Asthma. Evidence Report/Technology Assessment No. 91. AHRQ Publication No. 04-E013-2. Rockville, MD: Agency for Healthcare Research and Quality. March 2004. Résumé : www.ahrq.gov Texte intégral : www.ncbi.nlm.nih.gov
47. Atopy Risk in Infants and Children in Relation to Early Exposure to Fish, Oily Fish, or Long-Chain Omega-3 Fatty Acids: A Systematic Review. Kremmyda LS, Vlachava M, et al. Clin Rev Allergy Immunol. 2009 Dec 9.
48. Do early intake of fish and fish oil protect against eczema and doctor-diagnosed asthma at 2 years of age? A cohort study. Oien T, Storrø O, Johnsen R. J Epidemiol Community Health. 2010 Feb;64(2):124-9.
49. Omega-3 and omega-6 fatty acid exposure from early life does not affect atopy and asthma at age 5 years. Almqvist C, Garden F, et al; CAPS team. J Allergy Clin Immunol. 2007 Jun;119(6):1438-44.
50. Maternal diet during pregnancy in relation to eczema and allergic sensitization in the offspring at 2 y of age. Sausenthaler S, Koletzko S, et al; LISA Study Group. Am J Clin Nutr. 2007 Feb;85(2):530-7.
51. Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort. Brasky TM, Lampe JW, et al. Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1696-708.
52. Dietary {omega}-3 Fatty Acid and Fish Intake and Incident Age-Related Macular Degeneration in Women. Christen WG, Schaumberg DA, et al. Arch Ophthalmol. 2011 Mar 14.
53. Deutch B. Menstrual pain in Danish women correlated with low n-3 polyunsaturated fatty acid intake.Eur J Clin Nutr. 1995 Jul;49(7):508-16.
54. Harel Z, Biro FM, et al. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol 1996;174(4):1335-1338.
55. Deutch B, Jorgensen EB, Hansen JC. Menstrual discomfort in Danish women reduced by dietary supplements of omega-3 PUFA and B12 (fish oil or seal oil capsules). Nutr Res 2000;20(5):621-631.
56. Effect of Clupeonella grimmi (anchovy/kilka) fish oil on dysmenorrhoea. Moghadamnia AA, Mirhosseini N, et al. East Mediterr Health J. 2010 Apr;16(4):408-13.
57. Jacobs MN, Covaci A, et al. Time trend investigation of PCBs, PBDEs, and organochlorine pesticides in selected n-3 polyunsaturated fatty acid rich dietary fish oil and vegetable oil supplements; nutritional relevance for human essential n-3 fatty acid requirements. J Agric Food Chem. 2004 Mar 24;52(6):1780-8.
58. Persistent organic pollutants in fish oil supplements on the canadian market: polychlorinated dibenzo-p-dioxins, dibenzofurans, and polybrominated diphenyl ethers. Rawn DF, Breakell K, et al. J Food Sci. 2009 May;74(4):T31-6.
59. Persistent organic pollutants in fish oil supplements on the Canadian market: polychlorinated biphenyls and organochlorine insecticides. Rawn DF, Breakell K, et al. J Food Sci. 2009 Jan;74(1):T14-9.
60. The VITamin D and OmegA-3 TriaL (VITAL) http://www.vitalstudy.org
61. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Hartweg J, Perera R, et al.Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003205. Review.

1. Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol1990 Dec;66(6):639-41.
2. Marks LS, Partin AW, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000 May;163(5):1451-6.
3. Friederich M, Theurer C, Schiebel-Schlosser G. [Prosta Fink Forte capsules in the treatment of benign prostatic hyperplasia. Multicentric surveillance study in 2245 patients][Article en allemand, résumé en anglais]. Forsch Komplementarmed Klass Naturheilkd. 2000 Aug;7(4):200-4.
4. Tsai YS, Tong YC, et al. Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats. Urol Int. 2006;77(3):269-74.
5. Gossell-Williams M, Davis A, O'Connor N. Inhibition of testosterone-induced hyperplasia of the prostate of sprague-dawley rats by pumpkin seed oil. J Med Food. 2006 Summer;9(2):284-6.
6. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Hong H, Kim CS, Maeng S. Nutr Res Pract. 2009 Winter;3(4):323-7.

[1] Bagnis CI, Deray G, Baumelou A, Le Quintrec M, Vanherweghem JL. Herbs and the kidney. Am J Kidney Dis 2004;44:1—11. [2] De Smet PA. Herbal remedies. N Engl J Med 2002;347:2046—56. [3] Stewart MJ, Steenkamp V, Zuckerman M. The toxicology of African herbal remedies. Ther Drug Monit 1998;20:510—6. [4] Marcus Donald M. Botanical medicines — The need for new regulations. N Engl J Med 2002;347:2073—5. [5] Abuelo JG. Renal failure caused by chemicals, foods, plants, animal venoms, and misuse of drugs. An overview. Arch Intern Med 1990;150:505—10. [6] Gold CH. Acute renal failure from herbal and patent remedies in blacks. Clin Nephrol 1980;14:128—34. [7] Gessler MC, Msuya DE, Nkunya MHH, Schaˆr A, Heinrich M, Tanner M. Traditional healers in Tanzania: the perception of malaria and its causes. J Ethnopharmacol 1995;48:119—30. [8] Tabuti JRS, Dhillion SS, Lye KA. Traditional medicine in Bulamogi Country, Uganda: its practioners, users and viability. J Ethnopharmacol 2003;85:119—29. [9] Caille´ Y, Deray G, Bagnis CI. Les franc¸ais connaissent mal leurs reins. Re´sultats d’une enqueˆte sur les maladies re´nales re´alise´e aupre`s du grand public. Nephrol Ther 2007;3:55—9. [10] Kerharo J, Adam JG.In: La pharmacope´e traditionnelle : plantes me´dicinales et toxiques du Se´ne´gal. Paris: Vigot Fre`res e´diteurs; 1974. p. 1012. [11] Nacoulma Oue´draogo Odile. Plantes me´dicinales et pratiques me´dicales traditionnelles au Burkina Faso : cas du plateau central. The`se d’E´tat es sciences naturelles FAST Ouagadougou, tome 1 et tome 2 1996, 320 p. et 261 p. [12] Pousset JL. Plantes me´dicinales d’Afrique : utilisation pratique. Collection Ellipses 1989;155. [13] Fennel CW, Lindsey KL, McGaw LJ, Sparg SG, Stafford GI, Elgorashi EE, et al. Assessing African medicinal plants for efficacy and safety: pharmacological screening and toxicology. J Ethnopharmacol 2004;94:205—17. [14] Tidjani MA, Dieng C, Faye B, Diouf A. Etude de l’activite´ antiinflammatoire de Khaya senegalensis (A Juss) in vivo. Plantes me´dicinales et phytothe´rapie 1993;26:404—9. [15] Okoli AS, et Iroegbu CU. Evaluation of extracts of Anthocleista djalonensis, Nauclea latifolia and Livaria afzalii for activity against bacterial isolate from case of non-gonoccocal urethritis. J Ethnopharmacol 2004;22:135—44. [16] Lengani A, Guissou IP. Toxicologie des reme`des traditionnels au Burkina Faso : insuffisance re´nale aigue¨ et plantes me´dicinales. Annales de l’Universite´ de Ouagadougou se´rie B 1997;5: 111—20. [17] Laliberte´ MC, Norrmandeau M, Lord A, Lamarre D, Cantin I, Berbiche B, et al. Use of over-the-counter medications and natural products in patients with moderate and severe chronic renal insufficiency. Am J Kidney Dis 2007;49:245—56. [18] Ahmed MS, Hou SH, Battaglia MC, Picken MM, Leehey DJ. Treatment of idiopathic membranous nephropathy with the herb Astragalus membranaceus. Am J Kidney Dis 2007;50: 1028—32.